Highlights Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Real-time Estimate Cboe BZX Other stock markets 10:01:22 2024-04-29 am EDT			5-day change	1st Jan Change
14.71 ^USD	-0.14%		+0.20%	+10.07%

Mar. 27	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT
Mar. 07	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
ETF Preview: ETFs, Stock Futures Down Pre-Bell After Mortgage Applications Report	22-11-09	MT
Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	22-11-09	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-09	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-06	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-10	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-04	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-07	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Highlights

Filters